Table 1Included drugs

Active ingredient Dosage formTrade nameFormulationsaDaily maintenance dosageaIndications approved by the US Food and Drug Administration
Direct renin inhibitor (DRI)
Aliskiren Oral TabletTekturna®, Rasilez®bEQ 150–300mg base150–300 mg in 1 dose
Angiotensin converting enzyme inhibitor (ACE-I)
Benazepril Oral TabletLotensin®5–40 mg10–80 mg in 1 or 2 doses
Captopril Oral TabletCapoten®12.5–100 mg12.5–150 mg in 2 or 3 doses
Cilazaprilb Oral TabletInhibace®1–5 mg2.5–10 mg in 1 or 2 doses
Enalapril Oral TabletVasotec®2.5–20 mg2.5–40 mg in 1 or 2 doses
Fosinopril Oral TabletMonopril®10–40 mg10–80 mg in 1 or 2 doses
Lisinopril Oral TabletPrinivil®, Zestril®2.5–40 mg5–40 mg in 1 dose
Moexiprilc Oral TabletUnivasc®7.5–15 mg7.5–30 mg 1 or 2 doses
Perindopril Oral TabletAceon®, Coversyl®b2–8 mg4–8 mg in 1 or 2 doses
  1. The reduction of cardiovascular risk in patients with hypertension or post-myocardial infarction and stable coronary diseased
Quinapril Oral TabletAccupril®5–40 mg5–80 mg in 1 or 2 doses
Ramipril Oral Tablet, Oral CapsuleAltace®1.25–10 mg1.25–20 mg in 1 or 2 doses
  1. Reduction in the risk of myocardial infarction, stroke, death from cardiovascular causes
Trandolapril Oral TabletMavik®1–4 mg1–8 mg in 1 or 2 doses
  1. Heart failure post myocardial infarction, or left ventricular dysfunction post myocardial infarction
Angiotensin II receptor blocker (AIIRA)
Candesartan Oral tabletAtacand®4–32 mg8–32 mg in 1 dose
Eprosartan Oral TabletTeveten®EQ 400–600 mg base400–800 mg in 1 or 2 doses
Irbesartan Oral TabletAvapro®75–300 mg150–300 mg in 1 dose
Losartan Oral TabletCozaar®25–100 mg25–100 mg in 1 or 2 doses
  1. Hypertensive patients with left ventricular hypertrophy
Olmesartanc Oral TabletBenicar®5–40 mg20–40 mg in 1 dose
Telmisartan Oral TabletMicardis®20–80 mg40–80 mg in 1 dose
Valsartan Oral TabletDiovan®40–320 mg80–320 mg in 1 dose

Abbreviations: bid, twice daily; tid, 3 times daily; qd, once daily.

a

Obtained from the Medical Letter.

b

Only available in Canada.

c

Not available in Canada.

d

Indications for Coversyl only.

From: Introduction

Cover of Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers
Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report [Internet].
Norris S, Weinstein J, Peterson K, et al.
Portland (OR): Oregon Health & Science University; 2010 Jan.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.